Why do children with cerebral palsy discontinue therapy with botulinum toxin A?

Developmental Medicine and Child Neurology

Volumn 48, Issue 4, 2006, Pages 319-320

  Linder Lucht, Michaela ^a   Kirschner, Janbernd ^a   Herrmann, Jochen ^a   Geth, Katrin ^a   Korinthenberg, Rudolf ^a   Berweck, Steffen ^b   Heinen, Florian ^b   Mall, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CEREBRAL PALSY; CHILD; CHILDHOOD DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EMOTIONAL STRESS; HUMAN; LETTER; MOTOR PERFORMANCE; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SPASTICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANTIBODIES; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; HUMANS; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 33645029857     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S0012162206000697     Document Type: Letter

References (9)

1. Berweck S, Heinen F. (2004) Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 19 (Suppl 8): S162-S167.
2. Jefferson RJ. (2004) Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 46: 491-499.
3. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. (2000) Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15: 150-153.
4. Calace P, Cortese G, Piscopo R, Della Volpe G, Gagliardi V, Magli A, De Berardinis T. (2003) Treatment of blepharospasm with botulinum neurotoxin type A: Long-term results. Eur J Ophthalmol 13: 331-336.
5. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, Marchese R, Raineri R, Roselli F, Livrea P, Berardelli A. (2002) Botulinum toxin A treatment for primary hemifacial spasm: A 10-year multicenter study. Arch Neurol 59: 418-420.
6. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17: 1288-1293.
7. Palisano RJ. (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73: 651-658.
8. Herrmann J, Geth K, Mall V, Bigalke H, Schulte-Mönting J, Linder M, Kirschner J, Berweck S, Korinthenberg R, Heinen F, Fietzek UM. (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732-735.
9. Jankovic J, Vuong KD, Ahsan J. (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186-1188.